.
Improving Natural Glycopeptide Isolation Technology and Studying Their Immune-Modulating Properties (Stage II)
Project/agreement No.
KC-PI-2020/17
Project funding
160 281.00 EUR, including 144.252 EUR of ERDF funding and 16.029 EUR of RSU co-funding.
Project manager
Project realization
01.12.2021. - 30.06.2022.
Aim
The aim of the project is to develop glycopeptide isolation technology under industrial conditions, to test its qualitative properties and to conduct in-depth research on its immune-modulating properties.
Description
Stage II Commercialisation activities
1. Drafting of the commercialisation offer
- Cost estimates of the value of the developed test and of the licence offer
- Development of information and presentation materials for the commercialisation offer
2. Placement of the commercialisation offer on the market
- Participation in international contact exchange, brokerage events and fair.
- Communication with potential licensees
- Direct (individual) visits to potential licensees
3. Industrial research
- Technology optimisation and demonstration of immune-modulating properties
4. Drafting of the licence agreement and other legal documents required for the transfer of know-how
- Engagement of external experts for drafting of the licence agreement and other legal documents and to advise RSU on intellectual property (know-how) transfer to the potential licensee
5. Project management
- Administrative management of project activities in accordance with regulations of the Cabinet of Ministers, the terms of agreement with the Investment and Development Agency of Latvia (LIAA) and other applicable laws
